论文部分内容阅读
目的观察痰热清注射液联合利巴韦林治疗手足口病的临床疗效。方法将168例手足口病患儿随机分为治疗组和对照组各84例,对照组给予抗病毒利巴韦林等常规治疗,治疗组在上述常规治疗的基础上给予痰热清注射液治疗。比较2组临床疗效、不良反应及患儿体温下降、皮疹结痂和消退时间。结果治疗组总有效率为97.6%高于对照组的78.6%,差异有统计学意义(P<0.05);2组未发生明显的不良反应;治疗组患儿体温下降、皮疹结痂及消退时间均短于对照组,差异均有统计学意义(P<0.05)。结论痰热清联合利巴韦林治疗手足口病其临床症状及体征改善时间较单一应用利巴韦林缩短,疗效显著,且不良反应小,值得临床推广应用。
Objective To observe the clinical efficacy of Tanreqing Injection combined with ribavirin in the treatment of hand, foot and mouth disease. Methods 168 cases of hand-foot-mouth disease were randomly divided into treatment group and control group, 84 cases in each group, the control group was given anti-virus ribavirin and other routine treatment, the treatment group on the basis of the conventional treatment given Tanreqing injection . The clinical efficacy, adverse reactions, temperature drop, skin rash and regression were compared between the two groups. Results The total effective rate in the treatment group was 97.6%, which was significantly higher than that in the control group (78.6%, P <0.05). No significant adverse reactions occurred in the two groups. The body temperature decreased, rash and scab and subsidence time Both shorter than the control group, the difference was statistically significant (P <0.05). Conclusion Tanreqing combined with ribavirin treatment of hand, foot and mouth disease clinical symptoms and signs of improvement compared with a single application of ribavirin shortened, the effect was significant, and the adverse reactions small, worthy of clinical application.